Damien Pouessel

5.0k total citations · 1 hit paper
120 papers, 1.8k citations indexed

About

Damien Pouessel is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Damien Pouessel has authored 120 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Oncology, 57 papers in Surgery and 52 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Damien Pouessel's work include Bladder and Urothelial Cancer Treatments (51 papers), Urinary and Genital Oncology Studies (30 papers) and Cancer Immunotherapy and Biomarkers (27 papers). Damien Pouessel is often cited by papers focused on Bladder and Urothelial Cancer Treatments (51 papers), Urinary and Genital Oncology Studies (30 papers) and Cancer Immunotherapy and Biomarkers (27 papers). Damien Pouessel collaborates with scholars based in France, United States and United Kingdom. Damien Pouessel's co-authors include Stéphane Culine, Aude Fléchon, Stéphane Culine, Philippe Beuzeboc, Yohann Loriot, Philippe Barthélémy, Cora N. Sternberg, Petros Grivas, Manojkumar Bupathi and Scott T. Tagawa and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Damien Pouessel

108 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors

2021 351 citations Scott T. Tagawa, Arjun Vasant Balar et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Damien Pouessel

Since Specialization

Citations

This map shows the geographic impact of Damien Pouessel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Damien Pouessel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Damien Pouessel more than expected).

Fields of papers citing papers by Damien Pouessel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Damien Pouessel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Damien Pouessel. The network helps show where Damien Pouessel may publish in the future.

Co-authorship network of co-authors of Damien Pouessel

This figure shows the co-authorship network connecting the top 25 collaborators of Damien Pouessel. A scholar is included among the top collaborators of Damien Pouessel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Damien Pouessel. Damien Pouessel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Primary urethral cancer: Treatment patterns, responses and survival in localized, advanced and metastatic patients 2025 ·BJUI Compass ·(unknown), Aude Fléchon, G. Pignot, (unknown), J. Rigaud, M. Roumiguié, (unknown), Constance Thibault, Laurence Crouzet, (unknown), (unknown), Marine Gross‐Goupil, Luca Campedel, Mathieu Laramas, Thomas Filleron, E. Martin, Léonor Chaltiel, Damien Pouessel	0
2	Gut microbiota as a biomarker for the efficacy of pembrolizumab in patients with advanced urothelial carcinoma treated in a prospective multicenter study. 2025 ·Journal of Clinical Oncology ·(unknown), Lucia Grenga, Catherine Dunyach‐Remy, Guilhem Roubaud, P. Fournel, Aline Guillot, (unknown), Damien Pouessel, (unknown), R. Delva, Philippe Barthélémy, Stéphane Oudard, Constance Thibault, Diégo Tosi, Jean Armengaud, Nadine Houédé	1
3	A multicenter, open-label phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations (SURF301). 2025 ·Journal of Clinical Oncology ·Aaron R. Hansen, Alison Yan Zhang, Valentina Boni, Charlene Mantia, Evan Y. Yu, Andrew Weickhardt, Marie E. Robert, Shilpa Gupta, Rafael Morales‐Barrera, Christopher Hoimes, Jordan Berlin, Gopa Iyer, Michael Millward, Christine Lihou, (unknown), Damien Pouessel, Kriti Mittal, Andrew Hill, (unknown), Ben Tran	0
4	AVENANCE real-world study of avelumab first-line (1L) maintenance treatment for advanced urothelial carcinoma (UC): Analyses in low tumor burden subgroups. 2025 ·Journal of Clinical Oncology ·Philippe Barthélémy, (unknown), Constance Thibault, Aude Fléchon, Éric Voog, Jean Christophe Eymard, (unknown), Damien Pouessel, (unknown), Véronique Lorgis, Constant Josse, (unknown), (unknown), (unknown)	1
5	A plain language summary of the TROPHY-U-01 study: sacituzumab govitecan use in people with locally advanced or metastatic urothelial cancer 2024 ·Future Oncology ·Yohann Loriot, Arash Rezazadeh Kalebasty, Aude Fléchon, Rohit Jain, Sumati Gupta, Manojkumar Bupathi, Philippe Beuzeboc, Phillip L. Palmbos, Arjun Vasant Balar, Christos E. Kyriakopoulos, Damien Pouessel, Cora N. Sternberg, Julia Tonelli, (unknown), (unknown), Petros Grivas, Philippe Barthélémy, Rick Bangs, Scott T. Tagawa	1
6	GCISAVE: A non-comparative randomized phase II study of combination of gemcitabine cisplatin (GCis) +/- avelumab (A) in 1st line treatment for locally advanced or metastatic urothelial bladder carcinoma (MUBC)—GETUG AFU V07. 2024 ·Journal of Clinical Oncology ·Marine Gross‐Goupil, Éric Frison, Guilhem Roubaud, Aude Fléchon, Fabien Calcagno, Frédéric Rolland, Florence Joly, Anne‐Aurélie Raymond, (unknown), Philippe Barthélémy, Damien Pouessel, Constance Thibault, Stéphane Culine, Claude Linassier, Alain Ravaud	1
7	Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cancer 2023 ·Cancers ·Florent Puisset, (unknown), Loı̈c Mourey, Damien Pouessel, Benoı̂t Blanchet, Étienne Chatelut, Christine Chevreau	5
8	2379P AVENANCE: Subgroup analysis of patients (pts) with advanced urothelial carcinoma (aUC) with histological variants from a real-world (RW) study of avelumab first-line maintenance (1LM) 2023 ·Annals of Oncology ·Philippe Barthélémy, Yohann Loriot, Aude Fléchon, M. Gross Goupil, Éric Voog, (unknown), Véronique Lorgis, Damien Pouessel, (unknown), Christophe Sajous, (unknown), Aline Guillot, (unknown), Éric Amela, Constant Josse, (unknown), (unknown), Constance Thibault	2
9	2374P A phase Ib single-arm trial of bintrafusp alfa (BA) for pretreated, locally advanced/unresectable or metastatic (advanced) urothelial cancer (aUC) 2023 ·Annals of Oncology ·Petros Grivas, Srikala S. Sridhar, Begoña P. Valderrama, (unknown), Yohann Loriot, (unknown), Damien Pouessel, Michiel S. van der Heijden, Matthew D. Galsky, Shuchi Gulati, Alain Ravaud, Elisa Fontana, Alexander I. Spira, Benjamin A. Gartrell, Amir Mortazavi, Nicolás Isambert, (unknown), Tom Powles, (unknown), Rafael Morales‐Barrera	2
10	715P Nivolumab in pretreated metastatic penile squamous cell carcinoma: Results of the penile cohort from the French AcSé prospective program 2021 ·Annals of Oncology ·Damien Pouessel, M. Beylot‐Barry, (unknown), (unknown), Elodie Coquan, Hakim Mahammedi, Céline Gavoille, François Ghiringhelli, O. Dereure, (unknown), Diégo Tosi, Aude Fléchon, Diane Pannier, Paule Augereau, Laëtitia Gambotti, (unknown), (unknown), (unknown), Sylvie Chevret, Aurélien Marabelle	6
11	Survival Outcomes of Patients with Pathologically Proven Positive Lymph Nodes at Time of Radical Cystectomy with or without Neoadjuvant Chemotherapy 2020 ·Journal of Clinical Medicine ·Guillaume Ploussard, Benjamin Pradère, Jean‐Baptiste Beauval, Christine Chevreau, C. Alméras, Etienne Suc, Jean‐Romain Gautier, (unknown), M. Roumiguié, Guillaume Loison, Christophe Tollon, Loı̈c Mourey, Ambroise Salin, Évanguelos Xylinas, Damien Pouessel	9
12	1059P NEMIO: A randomized phase I-II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) + durvalumab +/- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma 2020 ·Annals of Oncology ·Constance Thibault, (unknown), Damien Pouessel, Aude Fléchon, Delphine Borchiellini, Philippe Barthélémy, Olivier Huillard, (unknown), (unknown), (unknown), François Audenet, Stéphane Oudard	4
13	LBA24 TROPHY-U-01 cohort 1 final results: A phase II study of sacituzumab govitecan (SG) in metastatic urothelial cancer (mUC) that has progressed after platinum (PLT) and checkpoint inhibitors (CPI) 2020 ·Annals of Oncology ·Yohann Loriot, Arjun Vasant Balar, Daniel P. Petrylak, Scott T. Tagawa, Arash Rezazadeh, Aude Fléchon, Rohit Jain, Neeraj Agarwal, Manojkumar Bupathi, Philippe Barthélémy, Philippe Beuzeboc, Phillip L. Palmbos, Christos E. Kyriakopoulos, Damien Pouessel, Cora N. Sternberg, Q. Hong, Trishna Goswami, Loretta M. Itri, Petros Grivas	19
14	Denosumab Toxicity When Combined With Anti-angiogenic Therapies on Patients With Metastatic Renal Cell Carcinoma: A GETUG Study 2018 ·Clinical Genitourinary Cancer ·Aline Guillot, (unknown), Philippe Barthélémy, (unknown), Sylvie Négrier, Damien Pouessel, Christine Chevreau, Hakim Mahammedi, Nadine Houédé, Guilhem Roubaud, Gwénaëlle Gravis, Sophie Tartas, Laurence Albigès, (unknown), Mathieu Oriol, Fabien Tinquaut, Sophie Espenel, Wafa Bouleftour, Stéphane Culine, Karim Fizazi	13
15	Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: a need of guidelines for treatment eligibility 2018 ·Modern Pathology ·Anissa Moktefi, Damien Pouessel, Jing Liu, Nanor Sirab, Pascale Maillé, Pascale Soyeux, Christiane Copie‐Bergman, (unknown), Dimitri Vordos, Alexandre de la Taille, Stéphane Culine, Yves Allory	26
16	P2.06-024 Tedopi vs Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Advanced NSCLC Patients in a Phase 3, Randomized Trial: ATALANTE-1 2017 ·Journal of Thoracic Oncology ·Benjamin Besse, Sylvestre Le Moulec, Julien Mazières, Damien Pouessel, István Albert, Giampiero Romano, Nicolas Girard, Éric Pichon, Olivier Molinier, C. Chouaïd, R. Corre, Jordi Remón, Rafał Dziadziuszko, Enriqueta Felip, Giuseppe Giaccone	1
17	Clinical and biological characteristics of non-small cell lung cancer (NSCLC) harbouring EGFR mutation: Results of the nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) 2016 ·Annals of Oncology ·Charlotte Leduc, Hélène Blons, Benjamin Besse, J.P. Merlio, D. Debieuvre, Antoinette Lemoine, I. Monnet, Damien Pouessel, P. P. Bringuier, M. Poudenx, Isabelle Rouquette, F. Vaylet, Franck Morin, Alexandra Langlais, Élisabeth Quoix, Gérard Zalcman, Denis Moro‐Sibilot, J. Cadranel, Michèle Beau‐Faller, Fabrice Barlési	2
18	Risk-adapted, dose escalation study of weekly docetaxel in the first-line treatment of elderly patients with advanced cancer 2012 ·Journal of Geriatric Oncology ·Stéphane Culine, C. Terret, Didier Cupissol, Gilles Romieu, Michel Fabbro, Damien Pouessel, Jean‐Pierre Droz, Sophie Gourgou	6
19	Targeted therapy in renal cell carcinoma 2008 ·World Journal of Urology ·Jean‐Jacques Patard, Damien Pouessel, Karim Bensalah, Stéphane Culine	36
20	Gemcitabine and docetaxel as front‐line chemotherapy in patients with carcinoma of an unknown primary site 2004 ·Cancer ·Damien Pouessel, Stéphane Culine, Catherine Becht, Marc Ychou, Gilles Romieu, Michel Fabbro, Didier Cupissol, Frédéric Pinguet	36

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact